Advertisement

European Journal of Clinical Pharmacology

, Volume 19, Issue 6, pp 431–435 | Cite as

Pharmacokinetics and biotransformation of benzbromarone in man

  • H. Ferber
  • H. Vergin
  • G. Hitzenberger
Originals

Summary

After administration of a single oral dose of benzbromarone 100 mg to 7 subjects, the maximum serum level was 1.84±0.87 mg/l, and the elimination halflife was 2.77±1.07 h. The major metabolite, benzarone, could be detected in serum 3 h after administration of benzbromarone, and the maximum serum benzarone level of 0.79±0.21 mg/l occurred after 6 h. Benzarone had an elimination half-life from serum of 13.52±2.18 h. Both substances were excreted mainly via the liver and bile. In urine only benzarone β-glucuronide could be detected; it amounted to 1.55% of the benzbromarone dose.

Key words

benzbromarone benzarone blood levels pharmacokinetics biotransformation excretion 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Zöllner N, Griebsch A, Fink JK (1970) On the effect of benzbromarone on serum uric acid levels and uric acid excretion in patients with gout. Dtsch Med Wochenschr 95: 2405–2412Google Scholar
  2. 2.
    Jain AK, Ryan JR, McMahon FG, Novek RJ (1974) Effect of single oral doses of benzbromarone on Serum and Urinary uric acid. Arthritis Rheum 17: 149Google Scholar
  3. 3.
    Kramp R, Lenoix R (1975) Distal permeability of urate and effects of benzofuran derivatives in the rat kidney. Am J Physiol 228: 875–883Google Scholar
  4. 4.
    Delbarre F, Auscher C, Oliver J, Rose A (1967) Traitement des hyperuricemics et de lagoutte par des clerives du benzofuranne. Sem Hop Paris 43: 1127–1133Google Scholar
  5. 5.
    Yu T (1976) Pharmacokinetics and clinical studies of a new uricosuric agent-benzbromarone. J Rheumatol 3: 305–312Google Scholar
  6. 6.
    Broekhuysen J, Pacco R, Sion L, Demeulenaese M, van Hel (1972) Metabolism of benzbromarone in man. Eur J Clin Pharmacol 4: 125–130Google Scholar
  7. 7.
    Rothe W, Schellhorn J (1977) Vorschlag einer Arzneibuchmethode zur Prüfung der Auflösungsrate von Wirkstoffen. Pharm Ind 39: 801–806Google Scholar
  8. 8.
    Vergin H, Bishop GB (1980) High-performance liquid chromatography determination of benzbromarone and its major metabolite benzarone in Serum. Chromatogr Biomed Appl 183: 383–386Google Scholar
  9. 9.
    Diamond HS (1978) Uricosuric drugs. In: Handbook of experimental pharmacology, Vol. 51, Chap 20. Springer, Berlin Heidelberg New York, pp 459–484Google Scholar
  10. 10.
    Broekhuysen J, Bekaert J, Rozenblum C, Deltour G (1965) Arch Int Pharmacodyn Ther 158: 165Google Scholar
  11. 11.
    Heel RC, Brodgen RN, Speight TM, Avery GS (1977) Benzbromarone: A review of its pharmacological properties and therapeutic use in gout and hyperurikaemia. Drugs 14: 349–366Google Scholar

Copyright information

© Springer-Verlag 1981

Authors and Affiliations

  • H. Ferber
    • 1
  • H. Vergin
    • 1
  • G. Hitzenberger
    • 1
  1. 1.Klinische Pharmakologie1. Medizinische UniversitätsklinikViennaAustria

Personalised recommendations